{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:30:35Z","timestamp":1787506235190,"version":"build-2736575974"},"reference-count":30,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2013,10,23]]},"published-print":{"date-parts":[[2014,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In paediatric pulmonary arterial hypertension (PAH), the effectiveness of add-on combination PAH-therapy has not yet been systematically studied. The purpose of this study was to determine the effect of sildenafil add-on therapy in paediatric PAH patients treated with bosentan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this observational study within a national paediatric patient cohort, follow-up data of 24 consecutive paediatric PAH patients initially treated with bosentan monotherapy and prospectively followed at the Dutch national referral centre for paediatric PAH in 2007\u20132013, were reviewed. Patients received add-on sildenafil therapy in case of clinical worsening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen children received add-on sildenafil therapy; nine remained on bosentan monotherapy. Patient characteristics, 6-minute walk distance (6MWD), WHO functional class (WHO-FC), N-terminal pro-Brain Natriuretic Peptide (NT-proBNP), and haemodynamic measurements at bosentan start were similar in both patient groups. In children with clinical worsening, sildenafil add-on therapy improved 6MWD at 5, 10, 15 and 21\u2005months of follow-up, improved WHO-FC at 10, 15 and 21\u2005months and stabilised NT-proBNP. Patients who received add-on sildenafil therapy had more advanced disease progression during bosentan monotherapy. Despite that, they had better or, at least, no worse survival compared to patients who remained on bosentan monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In children with PAH, sildenafil add-on therapy indicated by clinical deterioration on bosentan monotherapy, was associated with a significant improvement of WHO-functional class and 6MWD. Despite clinical deterioration on bosentan monotherapy, patients receiving sildenafil add-on therapy, had either better or, at least, no worse survival than patients remaining on bosentan monotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/heartjnl-2013-304895","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T09:28:22Z","timestamp":1388741302000},"page":"224-230","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre"],"prefix":"10.1136","volume":"100","author":[{"given":"Johannes M","family":"Douwes","sequence":"first","affiliation":[{"name":"Department of Paediatric Cardiology, Centre for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus T R","family":"Roofthooft","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, Centre for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa L E","family":"Van Loon","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, Centre for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-Jan","family":"Ploegstra","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, Centre for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrijs","family":"Bartelds","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, Centre for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans L","family":"Hillege","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Beatrix Children's Hospital, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf M F","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Paediatric Cardiology, Centre for Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,1,3]]},"reference":[{"key":"2025101801120757000_100.3.224.1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"2025101801120757000_100.3.224.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp297"},{"key":"2025101801120757000_100.3.224.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.02.023"},{"key":"2025101801120757000_100.3.224.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.026591"},{"key":"2025101801120757000_100.3.224.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.06.064"},{"key":"2025101801120757000_100.3.224.6","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2008.150086"},{"key":"2025101801120757000_100.3.224.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.06.003"},{"key":"2025101801120757000_100.3.224.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00075305"},{"key":"2025101801120757000_100.3.224.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00081706"},{"key":"2025101801120757000_100.3.224.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00051104"},{"key":"2025101801120757000_100.3.224.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.027"},{"key":"2025101801120757000_100.3.224.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2006.01692.x"},{"key":"2025101801120757000_100.3.224.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00005-5"},{"key":"2025101801120757000_100.3.224.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs094"},{"key":"2025101801120757000_100.3.224.15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200411-1587OC"},{"key":"2025101801120757000_100.3.224.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-004-0504-5"},{"key":"2025101801120757000_100.3.224.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.473371"},{"key":"2025101801120757000_100.3.224.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.016667"},{"key":"2025101801120757000_100.3.224.19","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2009.182378"},{"key":"2025101801120757000_100.3.224.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02012-0"},{"key":"2025101801120757000_100.3.224.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092311"},{"key":"2025101801120757000_100.3.224.22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.898122"},{"key":"2025101801120757000_100.3.224.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.911818"},{"key":"2025101801120757000_100.3.224.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2012.04.022"},{"key":"2025101801120757000_100.3.224.25","unstructured":"U.S. Food and Drug Administration. FDA drug safety communication: FDA recommends against use of revatio (sildenafil) in children with pulmonary hypertension. 2013;2013."},{"key":"2025101801120757000_100.3.224.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201210-1928PP"},{"key":"2025101801120757000_100.3.224.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.01.021"},{"key":"2025101801120757000_100.3.224.28","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.100388"},{"key":"2025101801120757000_100.3.224.29","unstructured":"Zijlstra WM Douwes JM Rosenzweig EB . Transatlantic survival differences in pediatric pulmonary hypertension: Clues to A better understanding of disease characteristics and treatment. American Thoracic Society International Conference Abstracts 2013;A3285."},{"key":"2025101801120757000_100.3.224.30","unstructured":"Ivy DD . 5th world symposium on pulmonary hypertension, pediatric task force, Chairman Dunbar D ivy. Nice, 2013."}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2013-304895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:12:12Z","timestamp":1760775132000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2013-304895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,3]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,1,3]]},"published-print":{"date-parts":[[2014,2,1]]}},"alternative-id":["10.1136\/heartjnl-2013-304895"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2013-304895","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,3]]}}}